Table 2.

Weights assigned to outcomes included in the benefit-harm analyses of low dose aspirin for primary prevention of cardiovascular disease and colorectal cancer

Outcome	5-year survival	Weight
Myocardial infarction [34]	79.2 %	0.5
Ischemic stroke [35]	42.0 %	1.0
Hemorrhagic stroke [35]	42.0 %	1.0
Gastrointestinal bleeds [36]	45.5 % (3-year)	1.0
Colorectal cancer [37]	65.2 %	0.5
Biliary cancer [37]	18.3 %	1.0
Esophageal cancer [37]	18.3 %	1.0
Gastric cancer [37]	30.3 %	1.0
Breast cancer [37]	89.6 %	0.5
Lung cancer [37]	18.0 %	1.0
Prostate cancer [37]	98.9 %	0.1
Hematological cancer [37]	48.5 –85.8 %	0.5
Pancreatic cancer [37]	7.9 %	1.0
Bladder cancer [37]	77.4 %	0.5
Gynecological cancer [37]	45.8 –81.6 %	0.5
Renal cancer [37]	73.6 %	0.5

These weights can be adjusted individually on [http://www.benefit-harm-balance.com]